MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)*
Organization & Developments: Recursion
Parents
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)*
Children
*AI-driven drug discovery platform for mRNA-based therapies.
*Artificial Intelligence (AI) based drug developer
*Digital drug discovery
*Recursion (NASDAQ: RXRX) is a clinical stage drug discovery company that combines automated imaging and artificial intelligence (AI) to rapidly identify therapeutic candidates via “phenomic” analysis.
2020: Recursion nabs $239M and an up to $1B partnership with Bayer as AI race heats up
2022: Recursion Pharmaceuticals: Approaching Drug Discovery Through AI_seekingalpha.com
2022: Recursion Pharmaceuticals: Destination Unknown_seekingalpha.com
2024: 3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
2024: Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
2024: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
2024: Recursion Completes Exscientia Merger, Creates AI Drug Discovery Powerhouse with $20B+ Pipeline
2024: Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress_ seekingalpha.com
2024: Recursion Pharmaceuticals’ (RXRX) Bold Acquisition Places it as an Industry Leader_www.tipranks.com
2024: Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
2024: Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform_seekingalpha.com
2024: Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245_seekingalpha.com
2025: AI specialist Recursion trims pipeline in latest shakeup
2025: As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials
2025: Recursion CEO launches pre-seed fund in response to NIH cuts
2025: Recursion lays off 20% of staff in wake of pipeline cutbacks
2025: Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest
2025: Recursion Pharmaceuticals, Inc. (RXRX) Nosedives 36.55% As AI Drug Discovery Dreams Stall
2025: Recursion Pharmaceuticals: Betting Big On AI_ seekingalpha.com
2025: Recursion Pharmaceuticals: High-Risk Play Getting Riskier By The Quarter
2025: Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky
2025: Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns
2025: Recursion rises on launch of Boltz-2 in partnership with MIT
2025: Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
2025: Recursion: Investors Will Need To Be Patient_ seekingalpha.com
2025: Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable
2025: Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline
2025: Time to show results on AI-driven drug development
Boltz-2, developed by the MIT Jameel Clinic and the public company, Recursion
Jumps
*Key People: Recursion
Finance & Acquisitions: Recursion